The Medicines and Healthcare products Regulatory Agency (MHRA) gave the go‑ahead for the Wegovy Pill this week, marking the first European approval of an oral version of the popular semaglutide weight‑loss drug. the tablet, which can be taken once daily, is aimed at adults with a BMI of 30 or higher, or 27‑30 with related health issues, and promises up to a 17% reduction in body weight over a year.

Private Pharmacies Ready to Stock Wegovy Pill Within Weeks

Major high‑street chains such as Boots, Superdrug and Morrisons are already preparing to dispense the medication through their in‑store health services, according to the source. the rapid rollout is driven by the pill’s convenience – a daily tablet replaces the weekly injection that many patients find intimidating.

Needle Phobia May Fuel 20% Uptick in Treatment Interest

Data cited in the report indicates that roughly one‑fifth of people considering pharmacological weight loss are deterred by fear of needles.. By eliminating the injection, Novo Nordisk hopes to broaden the drug’s appeal,especially among those who have avoided the 2.4 mg Wegovy shot.

Dosage Pathway Mirrors Injection Schedule, Up to 25 mg Tablet

The semaglutide tablet starts at 1.5 mg and can be titrated up to 25 mg , with each dose held for at least a month before escalation. Patients already on the 2.4 mg injection may swittch directly to the 25 mg pill, a flexibility highlighted by the source.

Public Access Stalls Until NICE Appraisal Completed

While private clinics can price the pill at their discretion, the National Health Service (NHS) has not yet adopted it. The National Institute for Health and Care Excellence (NICE) requires cost‑effectiveness evidence, which Novo Nordisk has not submitted, meaning public funding remains uncertain.

Projected Private‑Sector Demand Tops 120,000 in First Quarter

Industry analysts estimate that more than 120,000 adults could begin the private Wegovy Pill within the first three months, driven by a waiting list that is already swelling at online providers. With roughly 15 million Britons classified as obese, the potential market is massive.